Companies
G3T Therapeutics
Products
G3T - Model PILLAR 1 - Deep, ...

G3T - Model PILLAR 1 - Deep, Quantitative Precision Phenotyping Pharmaceutical Pipeline

We deployed non-invasive imaging in nearly all of our ~8,000 patients. These proprietary images are analyzed in a central core laboratory to quantify factors relating to disease states of interest, including:

Most popular related searches

coronary arterial

electronic medical record

Atherosclerotic plaque
Liver fat and fibrosis
Bone density
Muscle mass and muscle quality (fatty infiltration)

This data means we do not need to rely on electronic medical records, ICD-10 codes, what the patient or what the physician says – our data speaks for itself.

Characterising atherosclerotic coronary artery diseaseWe quantify the amount and precise composition of coronary arterial plaque

The core laboratory collects over 400 measurements and datapoints from the coronary arteries
We precisely quantify the composition of atherosclerotic plaques, including features of vulnerability that could contribute to rupture

Characterising fatty liver diseaseWe precisely quantify the amount of fat (“Steatosis”) and the amount of fibrosis in the liver

We identify the spectrum of fatty infiltration and the degree of fibrosis in all patients
We use sophisticated texture measurements and other liver features to quantify the degree of fibrosis in the liver
Liver biopsy is significantly limited by only evaluating a very small portion of the liver and is hindered by “geographic miss”. On the other hand, we evaluate the liver in totality and quantify liver fat and fibrosis in the entire organ

G3T - Model PILLAR 1 - Deep, Quantitative Precision Phenotyping Pharmaceutical Pipeline

Products Details